Trade Names:HepaGam B- Injection > 312 units/mL
Trade Names:HyperHEP B S/D- Injection 220 units/mL
Trade Names:Nabi-HB- Injection > 312 units/mLHYPERHEP B S/D (Canada)
Directly neutralizes hepatitis B virus (HBV).
T max is 6.5 ± 4.3 days ( Nabi-HB ); T max is 4 to 5 days ( HepaGam B ).
Vd is 11.2 ± 3.4 L ( Nabi-HB ); Vd is 7.5 L ( HepaGam B ).
Half-life is 23.1 ± 5.5 days ( Nabi-HB ); half-life is 22 to 25 days ( HepaGam B ); half-life is 17.5 to 25 days ( HyperHEP B S/D ).
Cl is 0.3 ± 0.12 L/d ( Nabi-HB ); Cl is 0.21 to 0.24 L/d ( HepaGam B ).
Prevention of hepatitis B infection following parenteral exposure (eg, needle stick), direct mucous membrane contact, or oral ingestion (eg, pipetting accident); prevention of hepatitis B in infants born to hepatitis B surface antigen (HBsAg)–positive mothers; prevention of hepatitis B after sexual exposure to an HBsAg-positive person; prevention of hepatitis B following household exposure to persons with acute HBV infections (eg, infants exposed to HBsAg-positive mother or caregiver); prevention of hepatitis B recurrence following liver transplantation in HBsAg-positive patients ( HepaGam B only).
Anaphylactic or severe systemic reaction to human globulin; thrombocytopenia or a coagulation disorder that would contraindicate IM injection.
IM 0.5 mL. Administer first HBIG dose as soon as possible, preferably less than 12 h after birth. Also give hepatitis B vaccine. Test patient for HBsAg and antibody to hepatitis B surface antigen (anti-HBs) at 12 to 15 months of age.Acute Exposure to Blood Containing HBsAg
IM 0.06 mL/kg as soon as possible after exposure and within 24 h plus hepatitis B vaccine series, if possible. For persons who refuse hepatitis vaccine or who are known nonresponders to vaccine, a second dose of HBIG should be given 1 month after the first dose.Sexual Exposure to an HBsAg-Positive PersonAdults
IM 0.06 mL/kg within 14 days of last sexual contact. Also give hepatitis B vaccine.Household Exposure to Persons With Acute HBV InfectionInfants younger than 12 months of age.
IM 0.5 mL. HBIG may be administered at the same time as, or up to 1 month preceding, hepatitis B vaccination.Liver Transplantation ( HepaGam B only)Adults
IV 20,000 units/dose. Coadminister the first dose with the grafting of the transplanted liver, then administer daily from day 1 to 7, then every 2 wk from day 14 to week 12 postoperative, and monthly from month 4 onwards. Administer at a rate of 2 mL/min. Decrease the rate to 1 mL/min or slower if patient develops discomfort or infusion-related adverse reactions, or if there is concern about the speed of the infusion.
Store vials in refrigerator (36° to 46°F). Do not freeze. Administer within 6 h after vial has been entered.
To avoid inactivating vaccines containing live viruses, give live vaccines 3 mo after HBIG.
HepaGam B : Product contains maltose, which can interfere with some types of blood glucose monitoring systems (ie, those based on glucose dehydrogenase pyrroloquinequinone method). Antibodies present in HepaGam B may interfere with some serologic tests.
Headache (14%); malaise (6%); agitation; amnesia; essential tremor; fatigue; light-headedness/fainting (3%); pyrexia.
Angioedema; pruritus; rash; urticaria.
Nausea (4%); vomiting (2%). Aphthous stomatitis; diarrhea; dyspepsia; gingival hyperplasia; infectious diarrhea.
Decreased WBC, ecchymosis (2%). Splenomegaly.
Elevated alkaline phosphatase (4%); elevated AST, elevated creatinine (2%).
Erythema (12%); aching (4%); pain, tenderness at the injection site.
Myalgia (10%); joint stiffness (2%). Back pain.
Pleural effusion; pneumonia.
Cold symptoms or flu (10%); anaphylactic reactions; liver transplant rejection; peripheral edema; sepsis.
Monitor liver transplant patients for serum anti-HBs antibody levels using a quantitative assay.
Category C .
Safety and efficacy in children not established ( HyperHEP B S/D , Nabi-HB ).
Use with caution in patients with a history of systemic allergic reactions following administration of human immune globulin products.
Because HBIG is made from human plasma, there is a risk of transmitting infectious agents (eg, viruses), including Creutzfeldt-Jakob disease.
Pain, tenderness at the injection site.
Copyright © 2009 Wolters Kluwer Health.